Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer

Exclusion Criteria

• •It will be accepted patients which would have begun new line of systemic treatment in the case where:
• •1. Hormonotherapy or CDK4/6 inhibitors ≤ 3 months.
• •2. Chemotherapy or immunotherapy ≤ 2 cycles. If SBRT arm: The treatment (except hormonotherapy by aromatase inhibitor and/or LHRH agonist) must be interrupted during the completion of radiotherapy.
• •a. Metastatic lesions out of previous radiation field b. Equal or less than 5 metastatic lesions (measurable or not) c. In case of measurable lesions, each ≤10 cm or ≤500 mL 8. For liver mets:
• •1. adequate liver function (liver enzyme \<3N, bilirubin\<30mg/dl, albumin\>2.5g/dl),
• •2. no underlying cirrhosis or hepatitis
• •3. liver metastase size ≤7cm diameter
• •4. not adjacent to stomach or small bowel 9. For abdominal mets:
• •a. Adequate renal function with a creatinine clearance (Cockroft formula) \> 60ml/min 10. Absence of any psychological, familial, sociological or geographical condition with a potential to hamper compliance with the study protocol and follow-up schedule 11. Life expectancy \> 3 months 12. Affiliated to Health Insurance regimen 13. Written and signed consent form